Business Standard

Dr Reddy's Labs looks to recover from Q1 blues with multiple growth drivers

Steady improvement in the US and India market growth keeps analysts positive

Drugs, Pharma, medicine
Premium

Ujjval Jauhari New Delhi
Dr Reddy’s lower-than-expected performance for the June quarter and delay in key product launches led to weakness in the stock, which shed 3.4 per cent on Tuesday. Disappointment with June quarter performance was led by temporary disruption in active pharmaceutical ingredient (API) manufacturing and one-off inventory adjustments.

The management, however, guided for a strong comeback of pharmaceutical services and active ingredient sales in the September quarter, on the back of a healthy order book and resolution of certain product-related issues in an API plant. Inventory adjustments are also not a matter of worry, according to analysts. The company in anticipation

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 30 2019 | 9:26 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com